Los Angeles Capital Management LLC Ultragenyx Pharmaceutical Inc. Transaction History

Los Angeles Capital Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	SELL	$62.2 - $84.4 $321,511 - $436,263	-5,169 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$73.71 - $87.86 $143,660 - $171,239	-1,949 Reduced 27.38%	5,169 $435,000
Q2 2021 Aug 05, 2021	SELL	$92.19 - $115.71 $266,060 - $333,939	-2,886 Reduced 28.85%	7,118 $679,000
Q1 2021 May 05, 2021	SELL	$106.9 - $167.73 $938,261 - $1.47 Million	-8,777 Reduced 46.73%	10,004 $1.14 Million
Q4 2020 Feb 04, 2021	BUY	$84.4 - $177.39 $8,524 - $17,916	101 Added 0.54%	18,781 $2.6 Million
Q3 2020 Nov 02, 2020	BUY	$72.98 - $90.0 $245,212 - $302,400	3,360 Added 21.93%	18,680 $1.54 Million
Q2 2020 Aug 05, 2020	BUY	$46.91 - $78.22 $106,016 - $176,777	2,260 Added 17.3%	15,320 $1.2 Million
Q1 2020 May 04, 2020	BUY	$33.8 - $62.9 $441,427 - $821,474	13,060 New	13,060 $580,000
Q4 2019 Feb 07, 2020	SELL	$36.08 - $45.83 $208,542 - $264,897	-5,780 Closed	0 $0
Q2 2019 Jul 29, 2019	SELL	$54.93 - $74.36 $578,962 - $783,754	-10,540 Reduced 64.58%	5,780 $367,000
Q1 2019 Apr 25, 2019	SELL	$39.87 - $69.36 $39,870 - $69,360	-1,000 Reduced 5.77%	16,320 $1.13 Million
Q4 2018 Feb 11, 2019	BUY	$38.89 - $77.3 $58,918 - $117,109	1,515 Added 9.59%	17,320 $753,000
Q3 2018 Nov 05, 2018	BUY	$71.81 - $90.15 $103,406 - $129,816	1,440 Added 10.02%	15,805 $1.21 Million
Q2 2018 Jul 31, 2018	SELL	$48.54 - $85.31 $18,445 - $32,417	-380 Reduced 2.58%	14,365 $1.1 Million
Q1 2018 Apr 27, 2018	BUY	$44.33 - $58.52 $653,645 - $862,877	14,745 New	14,745 $752,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.